 Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. NASDAQ: MNMD NEO: MMED DE: MMQ announced Friday the initiation of Phase 2a proof-of-concept trial of LSD lysergic acid diethylamide in adult patients with attention deficit hyperactivity disorder. The company said it expects to start patient enrollment soon, considering that the first site has been activated. 